Correlation between clinical response to hormone therapy and steroid receptor content in prostatic cancer.
Hormonal therapy is the dominating form of treatment for prostatic carcinoma. The majority of cases (80%) are well controlled for varying times with this regimen. However, thus far there have been no adequate methods to predict in which cases hormonal therapy is of less benefit. Measurement of cancer tissue content of intracellular hormone receptors constitutes progress toward a more individualized therapy in prostatic carcinoma. In this study biopsies from 16 cancer patients were taken before therapy was given, and the specimens were analyzed with regard to content of specific methyltrienolone-binding sites. A correlation has been made between receptor content and clinical response to hormonal therapy in each case. Twelve specimens contained measurable amounts of steroid receptors. Of these, one patient died during irradiation therapy before onset of hormonal treatment. However, of the remaining 11 patients, 9 responded well to hormones (9/11 approximately 82%). The two receptor-positive nonresponders had the lowest measurable receptor levels in the series. Four specimens contained no detectable amounts of receptors. Three of these patients showed no response to therapy (3/4 = 75%) but one was "false negative." Our data indicate that steroid receptor analysis may become a valuable diagnostic tool in individualizing the therapy for prostatic cancer.
D000368:Aged; D045166:Estradiol Congeners / Q000627:therapeutic use*; D005188:False Negative Reactions; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000032:analysis / Q000175:diagnosis / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000032:analysis / Q000175:diagnosis / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000032:analysis*; D011987:Receptors, Steroid / Q000032:analysis*; D012075:Remission, Spontaneous
D045166:Estradiol Congeners; D011944:Receptors, Androgen; D011987:Receptors, Steroid